ArticleCureus2026
Eucalyptol Ameliorates Neuroendocrine Stress-Aggravated Rheumatoid Arthritis Through Anti-inflammatory, Antioxidant, and Chondroprotective Mechanisms Associated with NF-κB and MAPK Signaling Pathways.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid arthritis (RA) is a lingering autoimmune disorder typified by synovial inflammation, oxidative imbalance, and advanced articular damage. Psychological and physical stress are known to exacerbate disease progression by enhancing inflammatory signaling and disrupting redox homeostasis. Although methotrexate remains a first-line therapy, its long-term use is accompanied by adverse effects, necessitating safer adjunctive strategies. Eucalyptol (1,8-cineole), a naturally occurring monoterpene, has demonstrated anti-inflammatory and antioxidant potential; however, its role in stress-aggravated RA remains inadequately explored.
objectiveTo evaluate the protective effects of eucalyptol in restraint stress-augmented Complete Freund's Adjuvant (CFA)-induced arthritis and to investigate its underlying mechanisms, both as monotherapy and in combination with methotrexate. METHODOLOGY: Experimental arthritis was induced in Wistar rats using CFA, followed by chronic restraint stress for 28 days. Animals were treated with eucalyptol (50, 100, or 200 mg/kg), methotrexate (1 mg/kg), or their combination. Disease progression was assessed using clinical scoring, functional parameters, biochemical assays, cytokine profiling, nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathway analysis, gene expression studies, and histopathological evaluation.
resultsRestraint stress significantly aggravated arthritic severity, resulting in increased oxidative and nitrosative stress, elevated pro-inflammatory cytokines, activation of NF-κB/MAPK signaling, and enhanced joint damage. Eucalyptol treatment produced significant dose-dependent improvements across these parameters. Notably, it reduced tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) levels while restoring antioxidant defenses. Combination therapy demonstrated the most pronounced therapeutic effect, with near normalization of multiple disease indicators.
conclusionsEucalyptol attenuates stress-exacerbated RA through integrated anti-inflammatory and antioxidant mechanisms. Its enhanced efficacy in combination with methotrexate highlights its potential as a complementary therapeutic strategy in RA management. Serum NF-κB and MAPK levels were used as surrogate markers of pathway involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.